Serum Cholinesterase Inhibition in Relation to Paraoxonase-1 (PON1) Status among Organophosphate-Exposed Agricultural Pesticide Handlers by Hofmann, Jonathan N. et al.
1402  v o l u m e  117 | n u m b e r 9 | September 2009  •  Environmental Health Perspectives
Research
Organophosphate (OP) and N-methyl-
carbamate (CB) insecticides inhibit cholin-
esterase (ChE) enzyme activity, including both 
serum ChE [butyrylcholinesterase (BuChE)] 
and erythrocyte ChE [acetyl  cholin  esterase 
(AChE)]. OP/CB insecticides are widely 
used in agriculture in the United States and 
abroad. Washington State is the nation’s 
leading producer of apples and several other 
tree fruits, and OP/CBs are applied in many 
orchards in eastern Washington. In 2004, 
the Washington State Department of Labor 
and Industries (WADLI) initiated a ChE 
monitoring program for agricultural pesti-
cide handlers who are exposed to toxicity 
cate  gory I or II OP/CBs (WADLI 2004). In 
this program, pesticide handlers (agricultural 
workers who apply pesticides or are otherwise 
involved in the pesticide application process) 
are tested for AChE and BuChE activities 
annually before the OP/CB spray season (i.e., 
at baseline), and during the spray season if 
they handle OP/CBs for ≥ 30 hr in a 30-day 
period. Handlers who are exposed only to 
CBs (not OPs) are not required to come in 
for follow-up ChE tests. Consequently, the 
vast majority of handlers in this monitoring 
program had been recently exposed to OPs 
over a period of several days to weeks at the 
time of their follow-up ChE test. Follow-up 
test results that show evidence of a decrease 
in AChE or BuChE activity from baseline 
levels can lead to work practice evaluations 
or removal from continued OP/CB exposure 
(with wage protection), depending on the 
degree of ChE inhibition observed.
Inhibition of AChE activity in the central 
and peripheral nervous systems is considered 
to be the main mechanism of OP/CB toxic-
ity (Ecobichon 2001). In addition to being 
found in the nervous system, AChE is pres-
ent on red blood cell membranes. BuChE 
is synthesized in the liver and is present in 
serum. Both AChE and BuChE activity can 
be measured in blood specimens as surro-
gates for neuronal AChE activity. Although 
AChE activity in blood is thought to more 
closely approximate neuronal AChE activ-
ity than does BuChE (Lotti 2001), both are 
considered valid markers of OP/CB-related 
biological effects by the U.S. Environmental 
Protection Agency (U.S. EPA 2000).
The health effects of acute OP/CB poison-
ings have been well characterized (Ecobichon 
2001), and a growing body of evidence sug-
gests that various health end points may be 
associated with chronic occupational OP/CB 
exposure. Previous studies have shown that 
OP exposure may be associated with deficits 
in neurobehavioral performance (Rothlein 
et al. 2006), chronic neurologic effects (Kamel 
and Hoppin 2004; Kamel et al. 2005), and 
several types of cancer (Alavanja et al. 2004).
It is possible that some individuals may be 
especially susceptible to health effects related 
to OP/CB exposure. High-density lipopro-
tein–associated paraoxonase-1 (PON1) is 
thought to be one important determinant of 
an individual’s sensitivity to some OP insecti-
cides, based primarily on evidence from stud-
ies in animal models (Cole et al. 2005; Li 
et al. 2000; Shih et al. 1998). PON1 hydro-
lyzes the highly toxic oxon forms of several 
widely used OPs, including chlorpyrifos and 
diazinon. PON1 does not hydrolyze all OPs 
(e.g., azinphos-methyl does not appear to be 
a PON1 substrate), and the role of PON1 
in metabolism of CBs has not been investi-
gated. Studies in transgenic mice have clearly 
demonstrated that low plasma PON1 activity 
is associated with greater brain AChE inhibi-
tion after exposure to chlorpyrifos oxon and 
diazoxon (the oxon forms of chlorpyrifos and 
diazinon) (Li et al. 2000). Also, a Q/R poly-
morphism at position 192 in the PON1 cod-
ing region affects the catalytic efficiency of the 
enzyme for chlorpyrifos oxon metabolism. In 
a study by Cole et al. (2005) of mice express-
ing equivalent levels of the different alloforms 
of humanized PON1, greater brain AChE 
inhibition was observed among mice with the 
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Ba c k g r o u n d: Animal studies have demonstrated that low paraoxonase-1 (PON1) status (i.e., low 
catalytic efficiency and/or low plasma PON1 activity) is associated with neurotoxic effects after 
exposure to several organophosphate (OP) insecticides. However, few human studies have investi-
gated associations between PON1 status and intermediate end points, such as serum cholinesterase 
[butyrylcholinesterase (BuChE)] inhibition, among OP-exposed individuals.
oBjectives: We evaluated the relation between plasma PON1 status and BuChE inhibition among 
OP-exposed agricultural pesticide handlers.
Me t h o d s : Agricultural pesticide handlers in Washington State were recruited during the 2006 and 
2007 spray seasons when they were seen for follow-up ChE testing by collaborating medical provid-
ers as part of a statewide monitoring program. Blood samples were collected from 163 participants 
and tested for PON1 status based on plasma PON1 activity [arylesterase (AREase)] and PON1 
Q192R genotype. We evaluated percent change in BuChE activity from baseline level in relation to 
PON1 status.
re s u l t s: We observed significantly greater BuChE inhibition among QQ homozygotes relative to 
RR homozygotes (p = 0.036). Lower levels of plasma PON1 activity were significantly associated 
with greater BuChE inhibition (p = 0.004). These associations remained after adjustment for year, 
days since baseline test, age, and OP exposure in the last 30 days.
co n c l u s i o n s: We found that both low PON1 catalytic efficiency (i.e., the Q192 alloform) and 
low plasma PON1 activity were associated with BuChE inhibition among OP-exposed agricultural 
pesticide handlers. Corroborative findings from future studies with prospective collection of blood 
samples for PON1 testing, more sensitive markers of OP-related effects, and larger sample sizes are 
needed.
key w o r d s : agriculture, cholinesterase, farmworkers, gene–environment interaction, organophos-
phates, paraoxonase, pesticides. Environ Health Perspect 117:1402–1408 (2009).  doi:10.1289/
ehp.0900682 available via http://dx.doi.org/ [Online 9 June 2009]PON1 status and BuChE inhibition among pesticide handlers
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Q192 alloform relative to the R192 alloform 
after chlorpyrifos oxon exposure.
Several important points should be con-
sidered regarding PON1-mediated sensitiv-
ity to OP exposure: a) PON1 status is most 
relevant for protection against direct expo-
sure to the oxon forms of OP insecticides 
(Li et al. 2000; Shih et al. 1998); b) most, if 
not all, OP exposures may include oxon resi-
dues (California Environmental Protection 
Agency 1998; Yuknavage et al. 1997); and c) 
the safety studies for OPs such as chlorpyrifos 
were carried out with the highly pure parent 
compound (Nolan et al. 1984).
Despite convincing evidence in animal 
models, few epidemiologic studies have evalu-
ated PON1 status as a determinant of OP 
sensitivity. We recruited agricultural pesticide 
handlers from the Washington State ChE 
monitoring program for a study to test the 
hypothesis that PON1 status affects an indi-
vidual’s risk of BuChE inhibition and is thus 
a biomarker of susceptibility.
Methods
Agricultural pesticide handlers in the state-
wide ChE monitoring program were recruited 
for this study from two collaborating clin-
ics in eastern Washington during the 2006 
and 2007 spray seasons (April–July). Blood 
samples for determination of PON1 status 
and self-reported OP/CB exposure informa-
tion were collected at the time of follow-up 
ChE testing during the spray season. A total 
of 163 participants with nonhemolyzed blood 
specimens for PON1 testing and both baseline 
and follow-up ChE tests were included in this 
analysis. This sample represents 54% of the 
304 handlers who were invited to participate. 
Study participants were similar to all handlers 
in the statewide ChE monitoring program in 
terms of age, race/ethnicity, and sex [Scientific 
Advisory Committee for Cholinesterase 
Monitoring (SAC) 2006]. We excluded one 
individual from this analysis because of hemo-
lysis in the plasma sample for PON1 testing. 
Some of the handlers enrolled in this study 
participated in both years (n = 25). For these 
individuals, the record with greater BuChE 
inhibition was included in the data set, and the 
other record was excluded (i.e., oversampling 
records with BuChE inhibition). Analyses 
were also repeated with random selection of a 
single record for these individuals who partici-
pated in both years.
In addition to collection of blood speci-
mens for PON1 testing, participants were asked 
to complete a computer-based survey regarding 
OP/CB exposure in the preceding 30 days and 
demographic characteristics. Surveys were com-
pleted by 141 of the participants included in 
this analysis. Another 11 participants had par-
tially complete surveys; nonmissing data from 
incomplete surveys were used where applicable.
This study was conducted in compli-
ance with all applicable U.S. requirements 
for research involving human subjects, and 
all study procedures were approved by the 
institutional review board at the University 
of Washington. Study participants provided 
written informed consent before participating 
in this study.
Determination of PON1 status. Handlers’ 
PON1 status was characterized based on gen-
otype at position 192 in the PON1 coding 
region and level of plasma PON1 activity. 
Genotype at position 192 was determined 
using a previously established TaqMan-
based genotyping assay (Applied Biosystems 
Inc., Foster City, CA) with genomic DNA 
extracted from EDTA-treated whole-blood 
specimens (Searles Nielsen et al. 2005). The 
genotype distribution was not significantly 
different from Hardy–Weinberg equilibrium 
expectations (p > 0.9).
The level of plasma PON1 activity was 
characterized by measuring arylesterase 
(AREase) activity in lithium heparin–treated 
plasma samples; AREase activity is consid-
ered to be a good surrogate for PON1 con-
centration in plasma (Furlong et al. 1993, 
2006). Phenylacetate was used as the sub-
strate in these assays, and hydrolysis rates were 
reported in units per milliliter.
BuChE measurements. All study partici-
pants were tested for annual baseline BuChE 
activity (generally a few weeks before the 
OP/CB spray season) and at follow-up dur-
ing the spray season as part of the statewide 
monitoring program. ChE test results were 
obtained from collaborating health care pro-
viders. Methods for collection and processing 
of blood specimens for ChE testing have been 
described previously (WADLI 2006). Because 
of an administrative change in the state pro-
gram, BuChE tests were performed by two 
different laboratories: the Washington State 
Public Health Laboratory (PHL; Shoreline, 
WA) in 2006 and Pathology Associates 
Medical Laboratories (PAML; Spokane, WA) 
in 2007. Baseline and follow-up BuChE tests 
were performed by the same laboratory within 
each year. Both laboratories measured BuChE 
activity using the Ellman method with 
reagents from Roche Diagnostics (Ellman 
et al. 1961). However, different instruments 
were used by each lab: The PHL used an 
automated Dade Dimension AR system, and 
PAML used an Olympus AU5421/AU2700 
system. Although absolute levels of BuChE 
activity differed between the two labs, both 
had high internal precision for BuChE mea-
surements. Coefficients of variation (CVs) 
were 2.5% for PHL in 2006 and 2.6% for 
PAML in 2007 (WADLI 2007).
In this study, we focused on BuChE inhi-
bition for several reasons. First, BuChE is 
more sensitive than is AChE to inhibition 
by many OPs, including chlorpyrifos, which 
was the most widely used OP among study 
participants (Amitai et al. 1998; Lotti 2001). 
Second, there was little evidence of AChE 
inhibition among study participants or among 
all handlers in the statewide monitoring pro-
gram. Among the 472 handlers in the state 
monitoring program who had baseline tests 
and at least one follow-up test in 2006, mean 
AChE inhibition was 1.8%, and only two 
handlers had “AChE depression” at the work 
practice evaluation threshold of > 20% inhi-
bition (SAC 2006). Finally, high variability in 
AChE measurements was observed in analyses 
of data from the state monitoring program 
in 2007 (CV, 16.7%) (WADLI 2007); this 
would likely have obscured any associations 
between PON1 status and AChE inhibition 
in our study.
Statistical analysis. The primary aim of 
this study was to test the hypothesis that low 
PON1 status is a determinant of BuChE inhi-
bition among OP-exposed pesticide handlers. 
For these analyses, PON1 status was charac-
terized in terms of both observed Q192R 
genotype and level of plasma PON1 activity 
(AREase activity). The primary end point was 
percent change in BuChE activity comparing 
levels at follow-up during the OP/CB spray 
season with preseason baseline levels. We con-
sidered the degree of change in BuChE to 
be the most biologically relevant end point 
because of wide interindividual variability in 
baseline BuChE activity (Cocker et al. 2002; 
Sidell and Kaminskis 1975). We also repeated 
analyses using follow-up BuChE activity as 
the outcome variable, with baseline BuChE 
activity included as a covariate in the model.
We performed several different analyses 
to characterize the relation between PON1 
status and BuChE inhibition. First, we evalu-
ated mean BuChE inhibition from baseline 
after stratifying by both Q192R genotype 
and tertiles of plasma PON1 activity. We 
compared the degree of BuChE inhibition 
within each stratum with the reference cat-
egory of individuals who were hypothesized 
to have the lowest risk (i.e., individuals with 
RR genotype and high plasma PON1 activ-
ity). Comparisons were based on linear regres-
sion with robust standard error estimates. We 
also performed linear regression with plasma 
PON1 activity modeled as a continuous pre-
dictor of BuChE inhibition after stratification 
by Q192R genotype.
We performed linear regression analy-
ses to evaluate BuChE inhibition by Q192R 
genotype and level of plasma PON1 activity 
with and without adjustment for   covariates. 
Analyses were also repeated after stratifying 
by year of participation. Adjusted models 
included both Q192R genotype and plasma 
PON1 activity, as well as year of participa-
tion, days since baseline ChE test, age in Hofmann et al.
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years, and cumulative OP/CB exposure score 
for the preceding 30 days. Age was reported 
by participants as part of the survey; for some 
participants with missing self-reported age 
(n = 19), we used birth dates from adminis-
trative records that were collected as part of 
the ChE monitoring program. Cumulative 
OP/CB exposure within the preceding 
30 days was estimated quantitatively based 
on survey responses regarding OP/CB use, 
work activities, and personal protective equip-
ment (PPE) use (Hofmann JN, unpublished 
observations). Briefly, we calculated a score 
for OP/CB toxicity based on data from U.S. 
EPA cumulative risk assessments, and scores 
for work activities and PPE use based on algo-
rithms developed as part of the Agricultural 
Health Study (Dosemeci et al. 2002; U.S. 
EPA 2005, 2006). Variables for OP/CB 
toxicity, work activities, and PPE use were 
transformed into z-scores, and cumulative 
OP/CB exposure was estimated by adding 
together the z-score values. Because plasma 
PON1 activity appeared to decrease slightly 
with increasing cumulative OP/CB exposure 
score, we treated OP/CB exposure score as a 
potential confounder, including it as a covari-
ate in all adjusted analyses.
In addition to linear regression analyses, we 
also used unconditional logistic regression to 
evaluate risk of “BuChE depression,” defined 
as > 20% BuChE inhibition from baseline 
activity level, by Q192R genotype and tertiles 
of plasma PON1 activity. We adjusted for the 
following covariates in this analysis: year of 
participation (2006, 2007), time since baseline 
ChE test (≤ 60 days, 61–90 days, > 90 days), 
age (18–24, 25–34, 35–49, ≥ 50 years), and 
cumulative OP/CB exposure score (< –0.85, 
–0.85 to 0.45, > 0.45).
We performed several exploratory analyses 
in this study. Linear regression analyses were 
repeated after restricting to chlorpyrifos-ex-
posed handlers, and after excluding handlers 
who reported only using CB insecticides. 
We also conducted linear regression analyses 
for BuChE inhibition in relation to Q192R 
genotype and level of plasma PON1 activity 
after stratifying by tertiles of OP/CB expo-
sure to evaluate whether the relations between 
PON1 status and BuChE inhibition differed 
by degree of OP/CB exposure.
All statistical analyses were performed using 
Intercooled Stata, version 9.2 (StataCorp, 
College Station, TX). Findings were considered 
statistically significant if p-values were < 0.05.
Results
Characteristics of study participants are 
reported in Table 1. All of the participants 
in this study were male, and all but one with 
reported ethnicity were Hispanic/Latino. 
Approximately 60% of study participants 
were < 35 years of age. In terms of reported 
OP/CB use in the preceding 30 days, chlo-
rpyrifos was the most widely used compound 
(67%), followed by carbaryl (30%) and 
azinphos-methyl (14%). Approximately two-
thirds of the study participants handled OP/
CB insecticides within the week before their 
follow-up ChE test (64%).
PON1 status and BuChE inhibition. 
Overall, participants in this study had sig-
nificantly lower BuChE activity at the time 
of follow-up during the OP/CB spray sea-
son relative to baseline (i.e., preseason) lev-
els (n = 163; p < 0.001, paired t-test). Mean 
BuChE inhibition from baseline activity was 
5.5% (range, –37.0% to 18.4%); this is con-
sistent with the degree of BuChE inhibition 
observed among all handlers in the state-
wide ChE monitoring program (SAC 2006). 
Relative to individuals with RR genotype and 
high plasma PON1 activity (i.e., hypothesized 
lowest risk individuals), those with either 
QQ genotype or low plasma PON1 activity 
had significantly greater BuChE inhibition 
(Table 2). Handlers with both QQ genotype 
and low plasma PON1 activity (i.e., hypothe-
sized highest risk individuals) had the greatest 
Table 2. BuChE inhibition (mean ± SD) after stratification by PON1 Q192R genotype and level of plasma 
PON1 activity (n = 163).a
Level of plasma PON1 activityb
Q192R genotype High Moderate Low p-Valuec






























ap-Values were determined based on linear regression with robust standard error estimates. bLevel of plasma PON1 
activity is based on AREase activity: high = > 145 U/mL; moderate = 124–145 U/mL; low = < 124 U/mL. cp-Value for trend 
by tertiles of plasma PON1 activity within each genotype.
Table 1. Characteristics of participants (n = 163).a 
aMissing values were excluded from percentages. Responses were missing if the participant did not complete the survey, 
did not know, or refused to answer. bParticipants could select multiple responses.
Characteristic No. (%)
Sex
  Male 163 (100.0)
  Missing 0
Race/ethnicity  
  Hispanic/Latino 139 (99.3)
  Non-Hispanic white 1 (0.7)
  Missing 23
Age (years)  
  18–24 27 (17.0)
  25–34 69 (43.4)
  35–49 52 (32.7)
  ≥ 50 11 (6.9)
  Missing 4
Level of education
  Did not attend school 5 (3.6)
  Did not complete primary school 16 (11.4)
  Primary school 51 (36.2)
  Middle school 54 (38.3)
  High school 15 (10.6)
  Missing 22
Able to read
  In Spanish 139 (98.9)
  In English 45 (31.9)
  Missing 22
Years employed as a pesticide handler
  ≤ 1 21 (19.3)
  2–3 33 (30.3)
  4–5 20 (18.4)
  6–10 21 (19.3)
  > 10 14 (12.8)
  Missing 54
Characteristic No. (%)
Location of home
  In town 68 (48.6)
  Rural area, away from orchards 21 (15.0)
  Rural area, near orchards 20 (14.3)
  In/next to orchards 27 (19.3)
  Other 4 (2.9)
  Missing 23
Reported OP/CB useb
  Chlorpyrifos 88 (66.7)
  Carbaryl 39 (29.6)
  Azinphos-methyl 19 (14.4)
  Dimethoate 11 (8.3)
  Malathion 6 (4.6)
  Other OP/CB 16 (11.2)
  Missing 31
Year of participation in study
  2006 89 (54.6)
  2007 74 (45.4)
  Missing 0
Time since baseline ChE test (days)
  ≤ 30 10 (6.2)
  31–60 115 (71.0)
  61–90 18 (11.1)
  > 90 19 (11.7)
  Missing 1
Days since last exposure
  Today/yesterday 18 (13.7)
  2–7 days ago 66 (50.4)
  > 7 days ago 47 (35.9)
  Missing 32
Survey language
  Spanish 148 (97.4)
  English 4 (2.6)
  Missing 11PON1 status and BuChE inhibition among pesticide handlers
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degree of BuChE inhibition of any group. A 
test for trend in BuChE inhibition by number 
of Q alleles and plasma PON1 activity levels 
was highly significant (n = 163, p = 0.002). 
Differences in AREase category frequencies 
within each Q192R genotype were not statis-
tically significant (p = 0.118, chi-square test).
Figure 1 shows the linear trend between 
BuChE inhibition and level of plasma PON1 
activity after stratification by Q192R genotype 
(n = 163). Based on this analysis, Q192R gen-
otype appears to modify the relation between 
plasma PON1 activity and BuChE inhibi-
tion. A highly significant association between 
lower plasma PON1 activity and greater 
BuChE inhibition was observed among RR 
individuals (n = 50, p = 0.001). This suggests 
that even individuals with the high catalytic 
efficiency genotype (192R homozygotes) for 
chlorpyrifos oxon hydrolysis may still be at 
risk of BuChE inhibition if they have low 
plasma PON1 activity. There was a border-
line significant relationship between plasma 
PON1 activity and BuChE inhibition among 
QR individuals (n = 81, p = 0.068), and we 
observed no association among QQ individu-
als (n = 32, p = 0.341). However, handlers 
with QQ genotype had significantly greater 
BuChE inhibition than did RR individuals 
(p = 0.036), which suggests that low catalytic 
efficiency of chlorpyrifos oxon hydrolysis may 
be a determinant of BuChE inhibition regard-
less of the level of plasma PON1 activity.
We also evaluated the degree of BuChE 
inhibition in relation to Q192R genotype 
and plasma PON1 activity after adjusting 
for covariates (Table 3). As in the unad-
justed analyses, QQ homozygotes had sig-
nificantly greater BuChE inhibition than did 
RR homozygotes after adjustment (n = 110, 
p = 0.03). We also observed a significant trend 
toward greater BuChE inhibition by number 
of Q alleles (p = 0.028). We observed a bor-
derline significant association between level of 
plasma PON1 activity (modeled as a continu-
ous predictor) and BuChE inhibition in the 
adjusted analysis (p = 0.053). Analyses strati-
fied by year of participation indicated that the 
associations between Q192R genotype and 
BuChE inhibition within each year were simi-
lar to the results of the main adjusted analysis. 
Although we observed greater BuChE inhibi-
tion with decreasing AREase activity in both 
years, this association was stronger in 2006 
than in 2007 (β = 0.073 and 0.039, respec-
tively). However, a test for interaction by year 
was not statistically significant (p = 0.529). 
Results of adjusted analyses evaluating fol-
low-up BuChE activity were generally con-
sistent with the results for BuChE inhibition 
(n = 110, p = 0.034 for QQ vs. RR genotype, 
and p = 0.066 for plasma PON1 activity). 
When we restricted the analyses to chlorpy-
rifos-exposed handlers, associations between 
BuChE inhibition and Q192R genotype and 
plasma PON1 activity after covariate adjust-
ment were similar in magnitude but no lon-
ger statistically significant (n = 69, p = 0.119 
for QQ vs. RR genotype, and p = 0.092 for 
plasma PON1 activity). Similarly, results were 
essentially unchanged after excluding 21 han-
dlers who reported using only CB insecticides 
(n = 89, p = 0.021 for QQ vs. RR genotype, 
and p = 0.094 for plasma PON1 activity). 
When analyses were repeated after a single 
record from handlers who participated in 
both years was selected at random (rather than 
sampling based on BuChE inhibition), similar 
results were obtained (data not shown).
As shown in Table 4, after adjustment 
for covariates, individuals with the QQ geno-
type were approximately 10 times as likely as 
RR individuals to experience BuChE depres-
sion (i.e., > 20% BuChE inhibition; n = 110, 
p = 0.036). Relative to individuals with high 
plasma PON1 activity, those with low plasma 
PON1 activity were three times as likely to 
have BuChE depression; this association was 
not statistically significant. However, when 
level of plasma PON1 activity was modeled as 
a continuous predictor, a statistically signifi-
cant decrease in odds of BuChE depression 
was observed with increasing plasma PON1 
Figure 1. BuChE inhibition in relation to level of plasma PON1 activity, stratified by PON1 Q192R genotype (n = 163). Coefficients based on robust linear regression 
























































































































































Plasma PON1 activity [AREase (U/mL)] Plasma PON1 activity [AREase (U/mL)] Plasma PON1 activity [AREase (U/mL)]
RR QR QQ
Table 3. BuChE inhibition in relation to PON1 Q192R genotype and level of plasma PON1 activity.
Unadjusteda Adjustedb
PON1 status No. β-Coefficient p-Value β-Coefficient p-Value
Q192R genotype 110 0.062c 0.028c
  RR 33 Reference — Reference —
  QR 55 –1.82 0.445 –3.36 0.130
  QQ 22 –5.72 0.056 –6.58 0.030
Level of plasma PON1 activityd 110 0.061 0.048 0.061 0.053
aQ192R genotype and level of plasma PON1 activity analyzed in separate models using linear regression with robust 
standard error estimates. This analysis was restricted to 110 records with nonmissing data for all covariates that were 
included in the adjusted model. bQ192R genotype and level plasma PON1 activity in same model, and adjusted for year of 
participation, days since baseline ChE test, age in years, and cumulative exposure score. Multiple linear regression with 
robust standard error estimates was used. cTest for trend by number of Q alleles. dBased on AREase activity (U/mL). The 
coefficient represents the difference in BuChE inhibition for a one-unit increase in AREase activity.
Table 4. Risk of > 20% BuChE inhibition by PON1 Q192R genotype and level of plasma PON1 activity after 
adjustment for covariatesa (n = 110).
PON1 status Cases (%)b Odds ratio 95% CI p-Value
Q192R genotype 0.033c
  RR 3 (9) Reference — —
  QR 7 (13) 4.02 0.62–26.16 0.146
  QQ 5 (23) 10.55 1.17–95.08 0.036
Level of plasma PON1 activityd 0.042e
  High 3 (8) Reference — —
  Moderate 4 (12) 1.48 0.17–13.28 0.726
  Low 8 (22) 3.01 0.43–21.30 0.269
aBased on unconditional logistic regression with Q192R genotype and tertiles of plasma PON1 activity in the same 
model, adjusted for year of participation (2006, 2007), days since baseline ChE test (≤ 60, 61–90, > 90), age (18–24, 25–34, 
35–49, ≥ 50 years), and cumulative OP/CB exposure score (< –0.85, –0.85 to 0.45, > 0.45). bCases defined as > 20% BuChE 
inhibition from baseline levels. Percentages refer to the proportion of cases within each stratum. cTest for trend by 
number of Q alleles. dBased on AREase activity high = > 145 U/mL; moderate = 124–145 U/mL; low = < 124 U/mL. eTest for 
trend by AREase activity modeled as a continuous variable.Hofmann et al.
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activity (p = 0.042). There were relatively 
few cases of BuChE depression in the study 
population (n = 15 for the adjusted analysis). 
Consequently, the confidence intervals for 
these odds ratios are fairly wide, and results 
should be interpreted with caution.
We also performed several analy-
ses to evaluate whether effect estimates for 
the association between PON1 status and 
BuChE inhibition differed by degree of 
OP/CB exposure. After stratifying by tertiles 
of OP/CB exposure score, we found that the 
magnitude of the association between QQ 
genotype (vs. RR genotype) and BuChE inhi-
bition increased with greater OP/CB expo-
sure (β = –3.38, –4.77, and –9.18 for low, 
medium, and high OP/CB exposure catego-
ries, respectively). We observed no such trend 
in the relationship between plasma PON1 
activity and BuChE inhibition after stratifica-
tion by OP/CB exposure.
Discussion
The relation between PON1 status and OP 
toxicity has been well characterized in animal 
models (Cole et al. 2005; Li et al. 2000; Shih 
et al. 1998). However, relatively few epidemi-
ologic studies have investigated PON1 status 
as a biomarker of susceptibility to OP-related 
effects. We found that both the PON1 Q192 
alloform and low plasma PON1 activity were 
determinants of BuChE inhibition among 
OP-exposed agricultural pesticide handlers. 
These findings are consistent with expectations 
based on results from animal studies (Cole 
et al. 2005; Costa et al. 2005a; Li et al. 2000).
Several previous studies have evaluated 
PON1-related sensitivity among OP-exposed 
individuals. A case–control study by Mackness 
et al. (2003) of self-reported chronic ill health 
among sheep dippers exposed primarily 
to diazinon indicated a 2.5-fold higher risk 
among farmers in the lowest quintile of diaz-
oxonase activity compared with the farmers in 
the highest quintile. However, that study did 
not take into consideration the fact that the R 
alloform of PON1 has somewhat better cata-
lytic efficiency for diazoxon than the Q allo-
form both in vitro and in vivo (Li et al. 2000; 
Richter et al. 2009). Another study by Lee 
et al. (2003) evaluated PON1 Q192R geno-
type among OP-exposed fruit farm workers in 
South Africa. Relative to RR individuals, those 
who were either QR heterozygotes or QQ 
homozygotes were almost three times as likely 
to report multiple (≥ 2) symptoms of chronic 
OP toxicity (e.g., abdominal pain, headache, 
gait disturbance, and limb numbness among 
other symptoms). In a case–control study of 
acute OP intoxication, Sozmen et al. (2002) 
found that cases had a significantly higher fre-
quency of the PON1 Q192 alloform and lower 
paraoxonase (POase) activity than did controls. 
They also found that POase activity was lower 
among cases with low BuChE activity upon 
hospital admission relative to cases with higher 
BuChE activity, suggesting a protective effect 
of PON1 against BuChE inhibition.
The association between low plasma 
PON1 activity and BuChE inhibition that 
we observed in this study is consistent with 
the results of some (Mackness et al. 2003; 
Sozmen et al. 2002) but not all (Perez-Herrera 
et al. 2008) studies that evaluated adverse 
health effects in relation to PON1 enzyme 
activity, even though different substrates to 
evaluate PON1 enzyme activity in several of 
these studies. The association between the 
Q192 alloform and greater BuChE inhi-
bition in this study is also consistent with 
findings from studies that evaluated symp-
toms of chronic pesticide toxicity (Lee et al. 
2003) and acute OP poisonings (Sozmen 
et al. 2002). However, other studies have 
reported associations between the R192 allo-
form and increased risk of chronic ill health 
(Mackness et al. 2003) and adverse effects 
on semen quality and sperm DNA integrity 
(Perez-Herrera et al. 2008). Inconsistencies in 
findings between studies may be attributable 
to exposure to different OP/CB compounds 
with varied toxic effects (Mackness et al. 
2003; Perez-Herrera et al. 2008) or evaluation 
of other health end points that are unrelated 
to ChE inhibition (Perez-Herrera et al. 2008).
This study had noteworthy strengths. By 
recruiting participants from the recently imple-
mented Washington State ChE monitoring 
program, we were able to establish a cohort of 
agricultural pesticide handlers with confirmed 
recent OP exposure. Because pesticide handlers 
(i.e., mixer/loader/applicators) are considered 
to be more highly exposed to pesticides than 
agricultural workers who perform other activi-
ties, this population is especially well suited 
for evaluating PON1-mediated susceptibility 
to OP exposure. Previous studies of PON1-
related susceptibility among individuals with 
occupational OP exposure have relied on self-
reported health outcomes such as chronic ill 
health (Mackness et al. 2003) or symptoms of 
chronic toxicity (Lee et al. 2003). In the pres-
ent study, we were able to use BuChE inhibi-
tion as a quantitative biomarker of OP-related 
effects as our primary outcome. Finally, some 
previous studies have relied exclusively on 
PON1 genotype. However, it is also important 
to consider the level of plasma PON1 activ-
ity, which can affect an individual’s ability to 
metabolize OPs at physiologically relevant rates 
independently of the Q192R polymorphism. 
For some (but not all) OPs that are metabo-
lized by PON1, the Q192R polymorphism 
is also important because it affects the cata-
lytic efficiency of OP hydrolysis. For example, 
both the Q192R genotype and the level of 
plasma PON1 activity affect chlorpyrifos oxon 
metabolism (Cole et al. 2005). Determination 
of both PON1 Q192R genotype and level of 
plasma PON1 activity in this study allowed for 
a better characterization of overall PON1 sta-
tus than available with genotype alone (Richter 
and Furlong 1999).
This study had several limitations. There 
is the possibility of uncontrolled confounding 
leading to inaccurate assignment of PON1 
status because PON1 activity may be modified 
to some extent by certain medications (e.g., 
statins), dietary habits (e.g., vitamin C and E 
intake), and environmental exposures (e.g., 
smoking) (Costa et al. 2005b; Durrington 
et al. 2002; Jarvik et al. 2002). However, very 
few participants in this study reported using 
cholesterol-lowering medications (2.4%), 
and risk estimates were essentially unchanged 
after controlling for smoking status (data not 
shown). Moreover, most previous studies sug-
gest that plasma PON1 activity levels tend 
to be relatively stable over time and are regu-
lated mostly by genetic factors, particularly 
the C108T promoter polymorphism (Brophy 
et al. 2001a, 2001b; Durrington et al. 2002; 
Ferre et al. 2003; Furlong et al. 2000; Jarvik 
et al. 2002; Leviev and James 2000; Suehiro 
et al. 2000; Zech and Zurcher 1974). Another 
limitation is the absence of PON1 and BuChE 
measurement data after the OP/CB spray sea-
son, which would help clarify the transient or 
persistent nature of effects. We are not aware 
of other similar studies that have included 
measurements before, during, and after the 
spraying season.
Absolute measurements of BuChE activ-
ity differed in 2006 and 2007 because of an 
administrative change in the laboratory con-
ducting ChE testing for the statewide moni-
toring program. However, within each year 
baseline and follow-up ChE tests were per-
formed by the same laboratory, so we were 
able to use the degree of BuChE inhibition 
from baseline levels as the main end point 
even though absolute BuChE measurements 
differed by year. Moreover, we included year 
of participation as a covariate in all adjusted 
models to control for differences by labora-
tory. Other newly developed biomarkers of 
OP exposure could potentially address con-
cerns about BuChE activity measurements 
and may be studied in the future (Quistad 
et al. 2005; Richards et al. 1999).
The relatively low participation rate in 
our study (54%) may be another limitation. 
However, study participants were similar to 
all participants in the statewide ChE monitor-
ing program in terms of demographic charac-
teristics and the degree of BuChE inhibition 
observed (SAC 2006), which suggests that 
our sample is likely to be representative of 
agricultural pesticide handlers participating in 
the ChE monitoring program in Washington 
State. Among study participants, missing 
data for some variables were also a concern. PON1 status and BuChE inhibition among pesticide handlers
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Approximately one-third of the records in 
the data set were excluded from adjusted 
analyses because of missing data. Most of 
the excluded records were missing data for 
the OP/CB exposure score variable because 
some participants provided blood samples 
for PON1 testing but did not complete the 
survey or were unable to identify specific OP/
CB insecticides used in the preceding 30 days. 
However, there did not appear to be any sub-
stantial differences in terms of PON1 status 
or BuChE inhibition between the records that 
were included in the adjusted analyses and 
records that were excluded.
Compared with RR individuals, rela-
tively few QQ individuals had low plasma 
PON1 activity. It is possible that these dif-
ferences in plasma PON1 activity levels by 
Q192R genotype may be attributable to 
the healthy worker survivor effect (e.g., QQ 
individuals with low PON1 activity might 
be more susceptible to pesticide-related ill-
ness and drop out of the work force before 
follow-up). However, given the relatively 
low frequency of acute pesticide-related ill-
nesses in this population (Washington State 
Department of Health 2008), such differences 
in plasma PON1 activity by Q192R genotype 
could also be explained by chance. Even if 
the healthy worker survivor effect is present, 
we would expect this type of bias to attenu-
ate any observed associations. Consequently, 
the associations observed in this study can be 
interpreted as conservative risk estimates.
Finally, although we had a larger sample 
size than most previous studies of PON1-
mediated OP sensitivity (Lee et al. 2003; Perez-
Herrera et al. 2008; Sozmen et al. 2002), this 
study had limited power to detect associations 
in the logistic regression analyses of BuChE 
depression and when evaluating interaction 
between OP/CB exposure score and PON1 
status in relation to BuChE inhibition.
Conclusions
In this study we found that both low PON1 
catalytic efficiency (i.e., the Q192 alloform for 
chlorpyrifos oxon hydrolysis) and low plasma 
PON1 activity were associated with BuChE 
inhibition among OP-exposed agricultural 
pesticide handlers. Regulatory risk assessments 
should take differences in PON1-related sen-
sitivity to OP insecticides into consideration 
when characterizing interindividual variabil-
ity in risk related to OP exposure. At some 
point in the future, biologic monitoring for 
PON1 status among pesticide handlers may 
be warranted to identify individuals who are 
at particularly high risk of OP-related health 
effects. However, issues of test validity as well 
as the ethical and legal aspects of genetic test-
ing in the workplace will need to be addressed 
before such a program could be implemented 
(Battuello et al. 2004).
Findings from this study need to be con-
firmed in future studies, which would ben-
efit from a) collection of blood specimens 
for determination of plasma PON1 activity 
before, during, and after exposure periods; 
b) evaluation of both AChE and BuChE inhi-
bition as end points; c) other newly developed 
biomarkers of OP exposure; and d) a larger 
sample size to assess interaction between the 
degree of OP exposure and PON1 status in 
terms of risk of BuChE inhibition.
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